• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - Chronic
Tag:

Chronic

Health

study reveals which fruit form is healthiest

by Chief Editor April 17, 2026
written by Chief Editor

The Evolution of the “Daily Fruit” Habit

For decades, the standard health advice has been simple: eat more fruit. However, recent data suggests that how we consume those fruits—whether we chew them, juice them, or blend them—could significantly alter the health outcomes.

View this post on Instagram about Fiber, Juicing
From Instagram — related to Fiber, Juicing

A study published in Frontiers in Nutrition indicates a surprising shift. While solid fruits have always been the gold standard, fruit smoothies are now being linked to some of the most favorable health markers, potentially outperforming both juices and even whole fruits in certain categories.

As we move toward more personalized nutrition, the focus is shifting from “how much fruit” to “which fruit form” best serves specific health goals, such as heart health or blood sugar regulation.

Did you grasp? According to recent research, fruit smoothie consumers reported significantly fewer physician visits—averaging 2.9 per year—compared to 4.9 visits for those who primarily consume fruit juice.

Why the Blend is Winning: The Fiber Factor

The primary battleground between juicing and blending is fiber. Juicing removes the solid parts of produce, such as the pulp, seeds, and skin, leaving only the liquid. In contrast, blending liquefies the entire fruit or vegetable, keeping the fiber intact.

Why the Blend is Winning: The Fiber Factor
Fiber Juicing Blending

This distinction is critical for gut health and metabolic stability. Fiber acts as a buffer, slowing the absorption of sugar into the bloodstream. When this fiber is removed, as it is in juice, you are left with a concentrated source of vitamins and phytonutrients, but without the protection against rapid blood sugar spikes.

Bioavailability vs. Blood Sugar

There is a delicate balance between nutrient absorption and glycemic response. Blending breaks down the cell structures in the pulp, which can actually improve digestibility and the absorption of nutrients while still retaining the fiber.

This represents why the trend is shifting toward smoothies for those seeking satiety and blood sugar regulation. Conversely, 100% fruit juices—such as pomegranate, beet, or tomato—remain a convenient way to get high concentrations of antioxidants and minerals in a highly bioavailable form, provided they contain no added sugars.

Pro Tip: To maximize the health benefits of a smoothie, focus on using whole fruits and vegetables to ensure you retain the fiber that supports digestion and helps you feel full longer.

Beyond the Plate: Mental Health and Systemic Wellness

One of the most intriguing findings in recent research is the link between fruit consumption forms and overall systemic wellness. The data reveals a stark contrast in the profiles of different consumers.

Study Reveals Declining Cognitive Function from Eating This Fruit

Smoothie consumers didn’t just report better physical health; they also showed the best self-rated mental health and the lowest prevalence of chronic diseases. Specifically, this group saw:

  • Hypertension: 19% prevalence.
  • High Cholesterol: 20% prevalence.
  • Diabetes: 8% prevalence.

In contrast, those who primarily consumed fruit juice had the highest prevalence of chronic diseases and the lowest health scores. After adjusting for risk factors, the odds of diabetes were 14.6 times higher in the fruit juice group compared to those who consumed little to no fruit.

This suggests that the future of dietary trends will likely link smoothie consumption not just to physical markers like BMI, but to mental health and a reduction in the need for prescription medications.

Future Shifts in Global Dietary Guidelines

Currently, many official frameworks, including the Dietary Approaches to Stop Hypertension (DASH) Diet and the Dietary Guidelines for Americans, primarily emphasize solid fruit and caution against sweetened beverages.

Future Shifts in Global Dietary Guidelines
Dietary Fiber Juicing

However, the evidence is mounting that fruit smoothies deserve a distinct place in these guidelines. Because smoothies are associated with a 60% lower odds of hypertension and a 70% to 80% reduction in the odds of cardiovascular disease and mental health issues compared to low-fruit consumers, they may soon be officially recommended as a viable alternative to solid fruit.

The next frontier in nutrition will likely involve longitudinal studies to move from “association” to “causation,” helping public health officials refine exactly how blending fits into a heart-healthy lifestyle.

Frequently Asked Questions

What is the main difference between a juice and a smoothie?
The main difference is fiber. Juicing extracts the liquid and removes the pulp, seeds, and skin. Blending processes the whole fruit or vegetable, retaining all the fiber.

Are smoothies actually healthier than whole fruit?
Some research suggests smoothies are associated with better health markers and improved nutrient absorption due to the breakdown of cell structures during blending, though both are generally healthier than juice.

Is any fruit juice healthy?
100% fruit juices without added sugar can provide essential vitamins and antioxidants. Nutrient-rich options include tomato, beet, and pomegranate juice.

Why are smoothies better for blood sugar than juice?
Smoothies contain the fiber of the whole fruit, which provides a buffering effect that slows the entry of sugar into the bloodstream, unlike juice which is a more concentrated source of sugar without fiber.


What’s your go-to morning routine—a fresh blend, a quick juice, or a piece of whole fruit? Share your experience in the comments below or subscribe to our newsletter for more evidence-based nutrition insights!

April 17, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Scientists link poor sleep to decreased chemotherapy response via the gut

by Chief Editor April 17, 2026
written by Chief Editor

The Hidden Link Between Sleep and Cancer Progression

For years, the medical community has acknowledged that sleep deprivation weakens the immune system. However, recent breakthroughs from the UF Health Cancer Institute have revealed a more complex mechanism: the gut microbiota. Researchers have discovered that the trillions of microorganisms residing in the human gut act as a critical conduit, driving the immune dysfunction caused by chronic sleep loss.

This discovery suggests that sleep deprivation doesn’t just develop you tired; it fundamentally alters the behavior and composition of your microbiome. These changes can accelerate tumor growth, disrupt the body’s natural circadian rhythms, and—most alarmingly—diminish the effectiveness of chemotherapy.

Did you know? Colorectal cancer has develop into the deadliest cancer in people younger than 50 in the United States, making the study of factors that accelerate its progression more urgent than ever.

How Sleep Loss Rewires Your Gut-Immune Axis

The relationship between the gut and the immune system is deeply interconnected. In a study led by graduate student Maria Hernandez, and Dr. Christian Jobin, researchers used murine models to simulate human chronic sleep deprivation. By transplanting stool samples from sleep-deprived mice into healthy, germ-free recipients, they were able to isolate the specific impact of the microbiota.

View this post on Instagram about Cancer, Sleep
From Instagram — related to Cancer, Sleep

The results were stark. Mice with a “sleep-deprived” microbiota experienced worse cancer progression, measured by increased tumor volume. The abundance of immune cells responsible for antitumor immunity was significantly reduced.

This suggests that the microbiome is the engine driving these negative outcomes. When sleep is compromised, the bacteria in the gut change, which in turn signals the immune system to lower its defenses against malignant cells.

The Future of Cancer Therapy: Beyond the Tumor

These findings are shifting the paradigm of oncology toward a more holistic approach. Rather than focusing solely on the tumor, future trends in cancer care are likely to prioritize the “whole patient,” including their sleep hygiene and gut health.

The Future of Cancer Therapy: Beyond the Tumor
Cancer Sleep Health

Microbiome-Based Drugs and “Good Bacteria”

Because the microbiota is “plastic”—meaning it can be modified—there is significant potential for new therapeutic interventions. Researchers are exploring ways to rebalance the gut by restoring “good bacteria” or developing targeted drugs to counteract the effects of sleep disruption.

Dr. Jobin’s lab has already pioneered methods to harvest the therapeutic potential of the microbiota, identifying molecules that can boost cancer treatment responses. Applying these techniques to sleep-induced microbiota changes could lead to a new class of supportive therapies for cancer patients.

Optimizing Chemotherapy Efficacy

One of the most critical findings involves 5-FU, the most common chemotherapy drug for colorectal cancer. The research demonstrated that sleep deprivation makes this drug less effective.

Scientists discover how poor sleep causes Alzheimer's

In the future, clinicians may integrate sleep data into treatment plans to ensure patients are in the best possible physiological state before receiving chemotherapy. By managing the microbiome through lifestyle or medical intervention, doctors may be able to recover the efficacy of these life-saving drugs.

Pro Tip: Since the microbiome is plastic, focusing on a healthy diet and consistent sleep patterns can help maintain the immune system’s ability to fight disease. Treat your microbiome with respect—It’s a living ecosystem that responds directly to your lifestyle.

Practical Steps for Microbiome Resilience

While hospitalized patients may struggle to get quality sleep, Notice evergreen strategies for those looking to support their gut-immune axis:

Practical Steps for Microbiome Resilience
Cancer Sleep Health Cancer Institute
  • Prioritize Sleep Consistency: Regular sleep patterns help maintain the circadian rhythms that regulate both the immune system and gut bacteria.
  • Dietary Support: A healthy diet supports a diverse microbiome, which can act as a buffer against the stressors of sleep loss.
  • Holistic Monitoring: Tracking sleep quality alongside other health markers can provide a clearer picture of your overall immune resilience.

For more information on how lifestyle factors impact health, you can explore resources from the UF Health Cancer Institute.

Frequently Asked Questions

How does sleep deprivation specifically affect cancer?
It alters the gut microbiota, which then triggers immune dysfunction. This leads to faster tumor growth, disrupted circadian rhythms, and a reduced response to chemotherapy.

Can the damage to the microbiome be reversed?
Yes. The microbiota is “plastic,” meaning it can be modified through lifestyle changes, such as improving sleep and diet, or potentially through future medical interventions like restoring “good bacteria.”

Why is the gut microbiome linked to the immune system?
The gut contains trillions of microorganisms that have a complex, interconnected relationship with the host’s immune cells, influencing how the body detects and fights tumors.

Join the Conversation

Do you think sleep quality should be a standard part of cancer treatment protocols? Share your thoughts in the comments below or subscribe to our newsletter for more insights into the future of oncology.

April 17, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Older adults show high willingness for Alzheimer’s blood tests

by Chief Editor April 15, 2026
written by Chief Editor

Alzheimer’s Blood Tests: A New Era of Early Detection and Patient Empowerment

For decades, the fear of Alzheimer’s disease has loomed large, often accompanied by uncertainty and delayed diagnoses. Now, a groundbreaking shift is underway, driven by the development of blood-based biomarker tests and a surprising willingness among patients to embrace them. A recent Northwestern Medicine survey reveals that over 85% of individuals would agree to undergo such a test if recommended by their doctor, signaling a potential revolution in how we approach this devastating disease.

The Anxiety Behind the Symptoms

Northwestern University psychologist Andrea Russell, who works directly with patients experiencing early cognitive changes, has witnessed firsthand the anxiety surrounding potential Alzheimer’s. Many patients worry over missed words, forgotten appointments, or fear making mistakes in public. This fear, coupled with the stigma associated with dementia, often prevents individuals from seeking timely medical evaluation.

The Anxiety Behind the Symptoms
Alzheimer Blood Early

From Invasive Procedures to a Simple Blood Draw

Traditionally, diagnosing Alzheimer’s involved costly and invasive procedures like PET scans and spinal taps, limiting access for many, particularly those in primary care settings. Blood-based biomarker tests offer a less invasive, more affordable alternative, detecting abnormal levels of amyloid and tau proteins associated with the disease. Although a couple of these tests received FDA clearance last year for individuals already exhibiting symptoms, their broader application is on the horizon.

What the Survey Revealed: Patient Perspectives

The Northwestern Medicine survey, encompassing nearly 600 primary care patients with an average age of 62, uncovered compelling insights. Before receiving information about the tests, 84% of respondents were unaware of their existence. However, after a brief explanation, 85% expressed willingness to undergo testing if recommended by their clinician. A significant 94% believed offering these tests to patients with memory or thinking problems was important.

Motivations for accepting the test centered around informed medical care (94%), insurance coverage (93%), comprehensive education (88%), and convenience (88%). Concerns revolved around cost (49%), test reliability (35%), fear of a positive result (22%), and potential differential treatment (24%).

Beyond Diagnosis: Empowering Proactive Brain Health

Interestingly, nearly three-quarters of participants anticipated emotional distress following a positive result, yet a remarkable 87% indicated they would likely grab steps to improve their brain health. This highlights a crucial point: even in the face of a potentially frightening diagnosis, individuals are motivated to take proactive measures.

Act For Older Adults

“What’s healthy for the brain is healthy for the body,” explains Russell. “If people learn they may be at higher risk, they may want to take action, such as managing chronic conditions, improving nutrition and staying engaged with their medical care. Those steps could help them prolong independence and well-being.”

The “New Cancer Diagnosis” and the Necessitate for Early Intervention

Russell describes Alzheimer’s as “the new cancer diagnosis” for many patients, noting their dissatisfaction with diagnostic delays, and uncertainty. Early detection isn’t just about confirming a diagnosis; it’s about empowering patients to plan ahead, access resources, and participate in clinical trials as researchers strive for better treatments. It similarly allows providers to intervene earlier, potentially slowing disease progression.

View this post on Instagram about Alzheimer, Blood
From Instagram — related to Alzheimer, Blood

Limitations and Future Directions

While promising, these blood tests aren’t without limitations. Results aren’t always conclusive, and a positive result doesn’t guarantee the development of dementia. Researchers are actively refining these biomarkers and exploring optimal implementation strategies within primary care settings. The tests measure proteins linked to amyloid plaques, and clinical trials have shown these tests closely match results from current gold standards.

Frequently Asked Questions

  • What do these blood tests measure? They measure proteins linked to amyloid plaques in the brain, a hallmark of Alzheimer’s disease.
  • Are the tests widely available now? While a few have received FDA clearance, they are not yet in widespread use.
  • Will a positive test result mean I definitely have Alzheimer’s? No, a positive result indicates an increased risk but doesn’t confirm a diagnosis.
  • What can I do if I’m concerned about Alzheimer’s? Talk to your doctor about your concerns and discuss whether a blood test or other evaluation is appropriate.

Pro Tip: Maintaining a healthy lifestyle – including regular exercise, a balanced diet, and social engagement – is crucial for brain health, regardless of your risk factors.

Did you know? Alzheimer’s disease is projected to nearly double by 2060, affecting an estimated 14.4 million older adults in the U.S.

Want to learn more about Alzheimer’s disease and the latest research? Visit the Alzheimer’s Association website for valuable resources and support.

April 15, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Waist-to-height ratio outperforms BMI in predicting hypertension risk

by Chief Editor April 15, 2026
written by Chief Editor

Waist-to-Height Ratio: A New Standard for Assessing Cardiovascular Risk?

For decades, Body Mass Index (BMI) has been the proceed-to metric for assessing weight and related health risks. But, a groundbreaking new study from the University of Eastern Finland and Robert Wood Johnson Medical School at Rutgers University suggests a more precise tool may be on the horizon: the waist-to-height ratio (WHtR). Research indicates that WHtR is a stronger predictor of hypertension than BMI, potentially revolutionizing how we screen for cardiovascular disease.

The Limitations of BMI

BMI, while widely used, has well-documented limitations. It fails to differentiate between fat mass and muscle mass. A muscular individual may be classified as “overweight” or even “obese” based on BMI, despite having a low percentage of body fat and a reduced risk of cardiometabolic diseases. This can lead to misdiagnosis and inappropriate health recommendations.

The Limitations of BMI

Why Waist-to-Height Ratio Matters

The WHtR offers a more nuanced assessment by measuring central obesity – the accumulation of fat around the abdomen. This type of fat is particularly linked to increased risk of heart disease, type 2 diabetes, and other health problems. A commonly recommended cut-off of WHtR 0.5 has been suggested by the UK National Institute for Clinical Excellence (NICE) to diagnose central obesity.

Study Findings: WHtR Outperforms BMI

The recent study, utilizing data from the US National Health and Nutrition Examination Survey (NHANES) spanning 2015-2023 and including over 19,000 participants, revealed compelling results. Individuals with high or excess fat mass as determined by WHtR were significantly more likely to have elevated blood pressure and hypertension. Specifically, those with excess fat had a 161% higher likelihood of hypertension. Interestingly, while BMI was associated with elevated blood pressure, it didn’t present a consistent link to hypertension itself.

Dr. Mahidere Ali, lead author of the study, emphasized that “BMI failed to detect the independent effect of adiposity, likely because it does not isolate the confounding influence of muscle mass.”

Implications for Public Health and Future Trends

These findings suggest a potential shift in how healthcare professionals assess cardiovascular risk. The simplicity and scalability of WHtR make it an attractive alternative or supplement to BMI. A WHtR calculator is available at https://urfit-child.com/waist-height-calculator/.

Looking ahead, we can anticipate several trends:

  • Increased Adoption of WHtR in Clinical Settings: More doctors may begin incorporating WHtR into routine check-ups, particularly for individuals at risk of cardiovascular disease.
  • Personalized Health Recommendations: WHtR can help tailor health recommendations based on an individual’s specific body composition and risk factors.
  • Refined Cut-off Points: Further research may refine WHtR cut-off points for different populations and age groups to maximize its accuracy.
  • Integration with Wearable Technology: WHtR could be integrated into wearable fitness trackers and health apps, providing individuals with real-time feedback on their cardiovascular risk.

WHtR in Youth: A Promising Indicator

The study similarly showed promising results in younger populations. While the association between WHtR and hypertension wasn’t statistically significant in those under 25 (likely due to the lower prevalence of hypertension in this age group), WHtR-assessed high and excess fat increased the likelihood of elevated blood pressure by 66% and 98%, respectively.

Rutgers School of Medicine: A Hub for Cardiovascular Research

The Robert Wood Johnson Medical School at Rutgers University, a key partner in this research, is poised to become a major force in medical education and research. As part of the future Rutgers School of Medicine, with anticipated accreditation in 2027, the institution will continue to drive innovation in cardiovascular health and other critical areas of medicine.

Frequently Asked Questions

What is WHtR?
Waist-to-height ratio is a measurement calculated by dividing your waist circumference by your height. It’s a simple way to assess central obesity.

How do I calculate my WHtR?
Measure your waist circumference and your height (in the same units). Then, divide your waist measurement by your height.

What is a healthy WHtR?
A WHtR of less than 0.5 is generally considered healthy. A WHtR of 0.5 or higher may indicate increased risk of health problems.

Is WHtR a replacement for BMI?
Not necessarily, but it offers a more nuanced assessment of cardiovascular risk. It’s best to discuss both measurements with your healthcare provider.

Where can I locate more information about this study?
You can find the study published in The Journal of Nutrition: https://doi.org/10.1016/j.tjnut.2026.101426

Pro Tip: Focus on a holistic approach to health, including a balanced diet, regular exercise, and stress management, alongside monitoring your WHtR.

Did you know? Increased muscle mass can actually *reduce* your risk of cardiometabolic diseases, highlighting the limitations of relying solely on BMI.

Have you discussed your WHtR with your doctor? Share your thoughts and experiences in the comments below!

April 15, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Study finds long COVID leaves a distinct immune signature in the blood

by Chief Editor April 15, 2026
written by Chief Editor

Unlocking Long COVID: New Protein Patterns Offer Hope for Diagnosis and Treatment

Recent research is shedding light on the complex biological mechanisms behind Long COVID, identifying distinct protein patterns in the blood that differentiate those still struggling with symptoms months after infection from those who have recovered. A study published in Communications Medicine reveals key inflammatory and neurological markers, offering potential avenues for improved diagnosis and targeted therapies.

The Persistent Puzzle of Long COVID

An estimated 5% to 30% of individuals infected with SARS-CoV-2 experience symptoms lasting months, a condition known as Long COVID. The core question remains: why do some fully recover while others face debilitating fatigue, brain fog, and chronic inflammation? Researchers are increasingly focused on immune dysregulation as a key factor, but identifying reliable biomarkers has proven challenging.

Key Protein Signatures Identified

The study, conducted on participants in Australia, compared blood samples from healthy individuals, those who had recovered from COVID-19, and individuals experiencing Long COVID. Researchers measured 182 inflammatory and neurology-related proteins, pinpointing several that stood out. Elevated levels of interleukin-20 (IL-20), macrophage chemoattractant protein-1 (MCP-1), and neuroblastoma suppressor of tumorigenicity 1 (NBL1) were particularly prominent in individuals with Long COVID, suggesting ongoing inflammation.

Interestingly, even those who had recovered from the initial infection showed some lingering protein differences compared to healthy controls, with fibroblast growth factor 19 (FGF-19) and cystatin D (CST5) associated with recovery status. This suggests that immune alterations can persist even after clinical recovery.

Pro Tip: Understanding these protein signatures could lead to the development of diagnostic tests to identify individuals at risk of developing Long COVID early on, allowing for proactive intervention.

Vaccination and Reinfection: A Shifting Immune Landscape

The research also investigated how vaccination and reinfection impact these protein patterns. Booster doses prompted strong antibody responses in all groups, but individuals with Long COVID and those who had previously recovered exhibited lower spike-specific antibody levels after breakthrough infections compared to those newly infected.

Crucially, the study found that the inflammatory patterns observed after the initial infection were not replicated following reinfection in individuals with Long COVID. This suggests the immune system reacts differently upon subsequent exposure to the virus.

Perhaps most reassuringly, vaccination did not worsen inflammation in individuals with Long COVID. in fact, inflammatory protein levels either stabilized or decreased. This reinforces the importance of vaccination, even for those experiencing long-term symptoms.

Implications for Future Research and Treatment

These findings represent a significant step forward in unraveling the complexities of Long COVID. Identifying these distinct immune alterations opens doors for developing targeted therapies aimed at modulating the immune response and alleviating symptoms. Further research is needed to validate these findings in larger cohorts and explore the potential of these protein markers as diagnostic tools.

The Role of Persistent Viral Presence

Emerging research suggests that the persistence of SARS-CoV-2 RNA or particles in tissues may play a role in driving the chronic inflammation seen in Long COVID. While the exact mechanisms are still being investigated, this persistent viral presence could be triggering ongoing immune dysregulation.

FAQ: Long COVID and Immune Response

Q: What is Long COVID?
A: Long COVID refers to symptoms that persist for weeks or months after the initial SARS-CoV-2 infection.

Q: Are vaccinations safe for people with Long COVID?
A: This study suggests vaccinations are well-tolerated and do not worsen inflammation in individuals with Long COVID.

Q: What are the key symptoms of Long COVID?
A: Common symptoms include fatigue, brain fog, and chronic inflammation.

Q: Can reinfection with SARS-CoV-2 worsen Long COVID?
A: The immune response to reinfection appears different than the initial infection, but this study did not find evidence of worsened inflammation.

Did you know? The number of symptoms associated with Long COVID exceeds 200, highlighting the diverse and individualized nature of the condition.

Wish to learn more about the latest research on Long COVID? Visit the CDC’s Long COVID page for up-to-date information and resources.

Share your experiences with Long COVID in the comments below. What symptoms have you experienced, and how has vaccination impacted your recovery?

April 15, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

tudy identifies intersectional biases affecting care for sickle cell patients

by Chief Editor April 13, 2026
written by Chief Editor

Sickle Cell Disease and the Fight Against Intersectional Bias in Healthcare

A poignant storyline in the first season of the show “The Pitt” – depicting a Black woman with sickle cell disease initially dismissed as drug-seeking in an emergency department – has sparked renewed attention to systemic biases within healthcare. This isn’t merely a fictional portrayal; experts confirm it reflects a harsh reality for many individuals living with sickle cell disease.

Unpacking the Layers of Bias

Recent research from the University of Chicago Medicine, published in JAMA Network Open, delves into the complex interplay of factors contributing to disparities in care. The study identifies that negative descriptors in clinician notes for sickle cell patients are closely linked to stigma surrounding opioid use, potentially overshadowing the impact of race or chronic pain alone.

View this post on Instagram

Monica Peek, MD, MPH, of UChicago Medicine, explains the challenge of pinpointing the source of discrimination. “Part of the issue for Black patients – and many marginalized groups – is that many in this population have multiple social identities that may be stigmatized… So when patients experience discrimination in healthcare, it is challenging to pinpoint what identity may be triggering the behavior.”

The Data Behind the Disparities

The UChicago Medicine study analyzed electronic health records of over 18,000 adults, examining nearly 40,000 clinician notes for negative descriptors like “aggressive,” “noncooperative,” and “noncompliant.” Findings revealed that patients with sickle cell disease had higher odds of these negative descriptors compared to Black patients and those with chronic pain. However, their odds were similar to patients with opioid use disorder, suggesting a strong connection between bias and opioid stigma.

This builds on previous research showing Black patients are more than 2.5 times more likely to have negative descriptors in their medical records compared to white patients. Further studies have demonstrated that biased language in patient records can lead to decreased clinician empathy and inaccurate recall of critical health details.

Beyond Stigma: The Reality of Pain Management

A key issue highlighted by researchers is the misconception surrounding opioid use in sickle cell disease. While patients often require opioid medications to manage chronic pain, the vast majority do not have an opioid use disorder. “Whereas patients with sickle cell disease routinely use opioid medications to manage their chronic pain, the vast majority do not have an opioid use disorder,” notes Peek. “It is a testament to the strength of their character that they do their best to live full lives while managing debilitating pain.”

Beyond Stigma: The Reality of Pain Management

Austin Wesevich, MD, emphasizes the importance of trust in the patient-clinician relationship. “Clinicians cannot measure pain directly without asking the patient, so it’s a choice to believe patients when they share their pain levels… a patient with sickle cell disease who experiences daily pain and who happens to be Black and asking for opioid treatment deserves no less trust than any other patient.”

Innovative Solutions: Anti-Bias Curriculum

Recognizing the need for change, UChicago Medicine has developed an anti-bias curriculum designed to mitigate these issues. The program utilizes skills-based learning through roleplay, coupled with education on how biases negatively impact care quality. Early data suggests the intervention is effective, with other institutions already expressing interest in adopting the curriculum.

Pro Tip: Healthcare organizations can proactively address bias by implementing similar training programs, promoting diversity within their staff, and fostering a culture of empathy and respect.

Future Trends in Addressing Healthcare Disparities

The focus on intersectional bias in sickle cell care signals a broader trend toward recognizing the complex factors influencing health outcomes. Expect to see increased use of natural language processing (NLP) and machine learning to identify and address bias in electronic health records. The development of standardized pain assessment tools and culturally sensitive communication strategies will be crucial.

The success of the UChicago Medicine intervention highlights the potential of targeted educational programs. Future initiatives may incorporate virtual reality simulations to provide clinicians with immersive experiences that challenge their biases and promote empathy.

FAQ

Q: What is sickle cell disease?
A: A genetic blood disorder that causes red blood cells to become sickle-shaped, leading to pain and other complications.

Q: Why are patients with sickle cell disease often stigmatized?
A: Stigma often stems from misconceptions about pain management and opioid use, as well as racial biases.

Q: What can be done to address bias in healthcare?
A: Implementing anti-bias training, promoting diversity, and fostering a culture of empathy are key steps.

Q: What role does technology play in identifying bias?
A: NLP and machine learning can analyze electronic health records to identify patterns of biased language.

Did you know? Patients with sickle cell disease often experience chronic pain that significantly impacts their quality of life. Effective pain management is essential, but often hindered by bias and stigma.

Learn more about sickle cell disease and ongoing research at the University of Chicago Medical Center.

What are your thoughts on this issue? Share your experiences and insights in the comments below!

April 13, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Lab study shows cigarette smoke damaged lung cells more than e-cigarette vapor

by Chief Editor April 13, 2026
written by Chief Editor

Cigarette Smoke vs. E-Cigarettes: Latest Research Reveals Stark Differences in Lung Cell Damage

A groundbreaking laboratory study published in Scientific Reports has revealed significant differences in how cigarette smoke and e-cigarette vapor affect human lung cells. Researchers at the University of Graz, Austria, found that cigarette smoke extract (CSE) caused substantial disruption to lung cell barriers, triggered inflammation, and damaged DNA, while e-cigarette vapor extract (EVE) showed no significant adverse effects under the same experimental conditions.

The Vulnerable Lung Barrier

Our airway epithelium acts as a crucial defense mechanism, protecting the body from inhaled particles and harmful substances. Cigarette smoke is well-established as a damaging agent to this barrier, contributing to conditions like chronic obstructive pulmonary disease (COPD). The question of whether e-cigarettes pose a similar threat has remained a subject of debate.

View this post on Instagram

This study utilized human Calu-3 lung epithelial cells, meticulously cultured and exposed to CSE and EVE. Researchers assessed barrier integrity, inflammation levels, and DNA damage using a range of sophisticated techniques, including Transwell systems, Western blotting, and DNA strand break assays.

CSE’s Damaging Effects: A Cascade of Cellular Disruption

The results were striking. CSE significantly reduced the electrical resistance of the cell barrier, indicating compromised cell cohesion and increased permeability. So harmful substances could more easily penetrate the lung tissue. CSE decreased the expression of key proteins – claudin-1 and occludin – essential for maintaining the integrity of the apical junctional complex, a critical component of the epithelial barrier. A 45% decline in claudin-1 levels was observed, highlighting its vulnerability to smoke exposure.

Inflammation also surged in cells exposed to CSE, with interleukin-6 (IL-6) levels increasing up to tenfold. Significant DNA damage, indicated by increased DNA strand breaks, was also detected. Notably, the study suggests that the damage caused by cigarette smoke isn’t solely attributable to nicotine, implying other toxic components are at play.

EVE: A Different Story

In stark contrast, EVE did not significantly impact barrier integrity, inflammation, or DNA damage. In some instances, it even appeared to slightly improve barrier stability. This suggests that, under the conditions tested in this in vitro model, e-cigarette vapor exerts less harmful effects on lung epithelial cells compared to cigarette smoke.

What Does This Imply for Public Health?

These findings offer valuable insights into the differing impacts of cigarette smoke and e-cigarette vapor on lung health. While CSE demonstrably disrupts cellular defenses, EVE did not exhibit the same detrimental effects. Though, researchers emphasize that this study was conducted in vitro, meaning in a laboratory setting, and doesn’t directly translate to human health outcomes.

The study used unflavored e-liquid, and the authors acknowledge that the use of liquid extracts rather than direct aerosol exposure may limit the generalizability of the findings. Further research, utilizing more representative biological systems, is crucial to fully understand the long-term health effects of e-cigarette vapor.

Pro Tip: Maintaining a healthy lung barrier is vital for overall respiratory health. Avoiding smoke exposure, whether from cigarettes or other sources, is a key step in protecting your lungs.

Future Trends in Respiratory Research

This study underscores a growing trend in respiratory research: the use of advanced in vitro models, like the Calu-3 cell system, to investigate the effects of inhaled substances. Expect to see more research focusing on:

  • Flavoring Chemicals: The impact of various e-liquid flavoring chemicals on lung cells is an area of increasing concern. Studies are beginning to assess the toxicity of cinnamon, vanilla tobacco, and hazelnut flavors.
  • Long-Term Exposure: Most studies to date have focused on short-term exposure. Longitudinal studies are needed to understand the cumulative effects of e-cigarette vapor over years or decades.
  • Individual Variability: Responses to inhaled substances can vary significantly between individuals. Research is exploring how genetic factors and pre-existing conditions influence susceptibility to lung damage.
  • Air-Liquid Interface (ALI) Models: Utilizing ALI models, which more closely mimic the lung environment, will provide more accurate and relevant data.

FAQ

Q: Does this study mean e-cigarettes are safe?
A: No. This study shows that, under the tested conditions, e-cigarette vapor appeared less harmful than cigarette smoke to lung cells. However, it does not prove e-cigarettes are entirely safe, and long-term effects remain unknown.

Q: What is the Calu-3 cell line?
A: Calu-3 is a human lung adenocarcinoma epithelial cell line commonly used in respiratory research to model lung function and responses to inhaled substances.

Q: What is the apical junctional complex?
A: The apical junctional complex is a protein network that forms a seal between lung epithelial cells, maintaining barrier integrity and preventing harmful substances from entering the body.

Q: What is IL-6?
A: IL-6 is an interleukin, a type of signaling molecule involved in inflammation. Elevated IL-6 levels indicate an inflammatory response.

Want to learn more about lung health and respiratory diseases? Explore our extensive library of articles on News-Medical.net.

April 13, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Rat hepatitis E virus may be a hidden cause of hepatitis in humans

by Chief Editor April 13, 2026
written by Chief Editor

The Hidden Hepatitis Threat: How Rat Hepatitis E Virus is Changing the Disease Landscape

A growing body of evidence points to a surprising source of hepatitis infections in humans: rats. Rat hepatitis E virus (ratHEV), previously considered a rodent-specific virus, is increasingly recognized as a zoonotic threat, prompting a reassessment of global hepatitis burdens and diagnostic approaches. Recent research, published in Nature Communications, details the virus’s ecology, transmission, and clinical impact, raising urgent questions about public health preparedness.

From Rodent Reservoir to Human Infection

For years, hepatitis E virus (HEV) was understood to be primarily transmitted through contaminated water, causing acute hepatitis. However, the discovery of human infection with a Rocahepevirus species in 2018 challenged this understanding. RatHEV, scientifically known as Rocahepevirus ratti, is now confirmed to spill over into humans, with cases reported across Asia, Europe, and even North America. Initial cases were often identified in individuals with unexplained chronic hepatitis, particularly liver transplant recipients.

From Rodent Reservoir to Human Infection

Understanding RatHEV: Genotypes and Viral Structure

Currently, the Rocahepevirus genus includes two species: Rocahepevirus eothenomi and R. Ratti. RatHEV itself has five genotypes (C1 to C5), but genotype C1 appears to be the primary driver of zoonotic transmission. This genotype circulates in both shrews and rats. The virus is a positive-sense, single-stranded RNA virus, with a genome encoding proteins crucial for replication and capsid formation. Genomic analysis reveals significant differences between ratHEV and traditional HEV.

Where is RatHEV Found and How Does it Spread?

RatHEV is widespread in rat populations, particularly in urban environments. Prevalence rates in trapped rats range from 10% to 30%, with higher rates observed in subtropical Asia and southern Europe. Transmission to humans likely occurs through contact with infected rat excreta or potentially through contaminated food or water. Pigs have been identified as potential transient hosts, capable of replicating the virus, and there’s some evidence of exposure in birds of prey, though their role in transmission remains unclear.

The Challenge of Diagnosis and Treatment

Diagnosing ratHEV infection is currently tough. Commercial assays are lacking, and existing antibody tests often show cross-reactivity with traditional HEV antibodies (between 10% and 70% for IgG, and 20% to 40% for IgM). Accurate diagnosis relies on detecting viral RNA through molecular testing, but even this requires multiple qPCR protocols to ensure comprehensive screening.

Clinical presentation mirrors that of HEV, ranging from asymptomatic infection to acute hepatitis, and, in severe cases, fulminant liver failure. In immunocompromised individuals, chronic hepatitis can develop. Treatment currently follows HEV protocols, primarily supportive care or ribavirin. The HEV genotype 1 vaccine may offer partial protection, but clinical efficacy data specifically for ratHEV are still needed.

Public Health Implications and Future Surveillance

The full extent of ratHEV’s impact on human health remains unknown. Systematic surveillance is limited, primarily focused on China and Western Europe. Integrating ratHEV into existing HEV surveillance guidelines could improve diagnosis rates and stimulate further research. International collaboration is crucial for developing standardized diagnostics, harmonizing surveillance efforts, and proactively addressing this emerging zoonotic threat.

FAQ: Rat Hepatitis E Virus

Q: How common is ratHEV infection in humans?
A: Prevalence varies geographically, ranging from less than 1% in some urban areas to as high as 22% in rural China.

Q: Can ratHEV cause chronic hepatitis?
A: Yes, particularly in immunocompromised individuals.

Q: Is the HEV vaccine effective against ratHEV?
A: It may offer partial protection, but more research is needed.

Q: How can I protect myself from ratHEV?
A: Practice good hygiene, avoid contact with rats and their droppings, and ensure proper food safety practices.

Did you know? RatHEV was initially considered strictly host-restricted to rodents, highlighting how our understanding of zoonotic viruses can evolve.

Pro Tip: If you experience unexplained hepatitis and have potential exposure to rats, inform your healthcare provider about the possibility of ratHEV infection.

Stay informed about emerging infectious diseases. Explore our other articles on viral hepatitis and zoonotic diseases to learn more.

April 13, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

EV-RNAs show promise for IBD diagnosis and treatment

by Chief Editor April 11, 2026
written by Chief Editor

The Future of IBD Treatment: Harnessing the Power of EV-RNAs

Inflammatory Bowel Disease (IBD), encompassing Crohn’s disease and ulcerative colitis, affects millions worldwide and is projected to impact over 1% of the population in early-industrialized countries by 2045. A recent comprehensive review published in ExRNA, led by researchers at Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, highlights a revolutionary approach to managing this chronic condition: extracellular vesicle-associated RNAs (EV-RNAs).

What are EV-RNAs and Why are They Essential?

EV-RNAs are essentially tiny “biological packages” secreted by cells, containing RNA molecules – including microRNAs and long non-coding RNAs – that act as messengers between cells. These vesicles play a crucial role in regulating the intestinal environment, influencing inflammation, and impacting the gut microbiome. Researchers are discovering that these molecules aren’t just bystanders in IBD, but key regulators that can be targeted for both diagnosis and treatment.

View this post on Instagram

Non-Invasive Diagnosis: A Game Changer

Currently, diagnosing IBD often requires invasive endoscopic examinations. EV-RNAs offer a potential solution with non-invasive biomarkers detectable in easily accessible fluids like plasma and even saliva. Studies cited in the ExRNA review demonstrate remarkably high accuracy – with area under the curve (AUC) values ranging from 0.95 to 0.97 – in distinguishing active IBD from remission using specific EV-RNA signatures, such as elevated levels of long non-coding RNA H19 in plasma EVs.

Pro Tip: The ease of sample collection (saliva, blood) could dramatically improve patient compliance and enable more frequent monitoring of disease activity.

EV-RNA-Based Therapies: Beyond Traditional Approaches

Traditional IBD treatments, like anti-inflammatory drugs and biologics, often come with systemic side effects and can lead to drug resistance. EV-RNA-based therapies offer a more targeted approach. Several strategies are showing promise in preclinical models:

  • Mesenchymal Stem Cell-Derived EVs (MSC-EVs): These EVs carry immunomodulatory miRNAs that can suppress inflammation and promote intestinal barrier repair. They offer a safer alternative to whole-cell stem cell therapy, with a lower risk of immune rejection.
  • Dietary and Plant-Derived EVs: EVs extracted from sources like bovine colostrum, Coptis chinensis, Centella asiatica, and tea contain functional miRNAs that can survive digestion and directly target inflamed intestinal tissues. For example, EVs from Coptis chinensis can restore zinc homeostasis in immune cells, reducing intestinal damage.
  • Engineered EVs: Researchers are modifying EVs to deliver therapeutic RNAs directly to inflamed tissues, offering personalized treatment options for patients who don’t respond to conventional therapies.

Systemic Impact: Addressing Extraintestinal Complications

IBD isn’t limited to the gastrointestinal tract. It’s often associated with complications affecting the liver and heart. The research highlights that EV-RNAs secreted by inflamed intestinal tissues can travel through the bloodstream and influence inflammatory responses in distant organs, providing a molecular link to these systemic issues.

Systemic Impact: Addressing Extraintestinal Complications

Did you know? Understanding the systemic role of gut-derived EV-RNAs could lead to therapies that prevent or mitigate these extraintestinal complications.

Challenges and Future Directions

Despite the exciting potential, several challenges remain. Standardized protocols for EV isolation, purification, and RNA detection are crucial to ensure consistent results across laboratories. Large-scale clinical trials are needed to validate the efficacy of EV-RNA-based diagnostics and therapies in human patients, and clear regulatory pathways for these novel treatments must be established.

Frequently Asked Questions (FAQ)

Q: What is the difference between Crohn’s disease and ulcerative colitis?
A: Crohn’s disease can affect any part of the digestive tract with transmural inflammation, although ulcerative colitis is limited to the colorectal mucosa with superficial inflammation.

Q: Are EV-RNA therapies currently available for IBD patients?
A: No, EV-RNA therapies are still in the preclinical and early clinical stages of development. More research and clinical trials are needed before they become widely available.

Q: How can I learn more about EV-RNA research?
A: You can explore the research published in the journal ExRNA and follow updates from leading research institutions like Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine.

The field of EV-RNA research is rapidly evolving, offering a beacon of hope for the millions affected by IBD. As research progresses and challenges are addressed, these tiny vesicles could revolutionize the way we diagnose, monitor, and treat this debilitating disease.

Want to stay informed about the latest advancements in IBD research? Subscribe to our newsletter for updates and insights from leading experts.

April 11, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

New clinical guidelines address blood clot prevention in pediatric patients

by Chief Editor April 8, 2026
written by Chief Editor

New Guidelines Offer Clarity in Pediatric Blood Clot Prevention

The American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) have jointly released comprehensive clinical practice guidelines addressing anticoagulant prophylaxis in non-cardiac pediatric patients at risk of venous thromboembolism (VTE). Published in Blood Advances, these guidelines aim to standardize care for a vulnerable population where preventative strategies have historically lacked consensus.

The Rising Concern of Pediatric VTE

Venous thromboembolism, the formation of blood clots in veins, is becoming increasingly common in children, particularly those hospitalized or managing chronic conditions like cancer. Hospital-acquired VTE is now the second most common cause of preventable harm in children. Previously, much of the data used to guide VTE prevention in pediatric patients was extrapolated from adult studies, which often don’t accurately reflect the unique risk profiles of children.

View this post on Instagram

Key Recommendations for Prophylaxis

The new guidelines, developed by a multidisciplinary expert panel including a lived experience expert, present twelve recommendations and two fine practice statements. These address the complex decision-making process surrounding anticoagulant prophylaxis. Specifically, the guidelines offer conditional recommendations suggesting:

  • No anticoagulant prophylaxis for children with solid cancer, trauma, or critical illness.
  • Anticoagulant prophylaxis for children with antiphospholipid syndrome or those on long-term total parenteral nutrition.

The guidelines as well provide counsel on administering prophylaxis to children with acute lymphoblastic leukemia, lymphoma, a central venous access device, or those who have recently undergone surgery.

Addressing Gaps in Care and Future Research

Recognizing the necessitate for ongoing improvement, the guidelines emphasize the importance of standardized protocols for managing interruptions to therapy, particularly during procedures like lumbar puncture or spinal anesthesia. The expert panel highlighted the need for further research to develop VTE risk assessment models specifically tailored for pediatric populations and to evaluate the safety and efficacy of prophylaxis across different subgroups of children.

“These guidelines provide physicians with an evidence-based framework to make decisions about VTE prophylaxis for children,” said Marisol Betensky, MD, MPH, co-chair of the guidelines.

The Importance of Collaboration

“This patient group is often among the most vulnerable and medically complex we treat, and clinicians have long lacked clear guidance on how to best care for them,” stated ASH President Robert Negrin, MD. The collaboration between ASH and ISTH underscores a shared commitment to advancing evidence-based care and improving outcomes for children worldwide.

The Importance of Collaboration

Resources for Healthcare Professionals

Additional resources, including visual summaries and teaching slides, are available at hematology.org/VTE. ASH and ISTH have also previously developed revised clinical practice guidelines for pediatric VTE treatment.

Frequently Asked Questions

What is VTE? VTE stands for venous thromboembolism, which is the formation of blood clots in veins.

Why are these guidelines significant? They provide a standardized approach to preventing blood clots in children, a population where preventative care has been historically unclear.

Where can I find more information? Visit hematology.org/VTE for additional resources.

Pro Tip: Always consider the individual patient’s risk factors and clinical presentation when making decisions about anticoagulant prophylaxis.

Stay informed about the latest advancements in pediatric hematology. Explore more articles on our website and subscribe to our newsletter for updates.

April 8, 2026 0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Recent Posts

  • Provincial Economic Information Center Promotes Correct View of Political Achievements to Advance Digital Fujian

    April 17, 2026
  • US-Iran Nuclear Deal Near as Strait of Hormuz Reopens

    April 17, 2026
  • Trump Forbids Israel From Bombing Lebanon Following Ceasefire

    April 17, 2026
  • Zestien Jaar in een Bubbel

    April 17, 2026
  • Asseco Resovia Rzeszów vs Aluron CMC Warta Zawiercie: How to Watch PlusLiga Semi-Final

    April 17, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: o f f i c e @byohosting.com


Back To Top
Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World